BLASUBCUTANEOUSINJECTABLE
Approved
Aug 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FOLLISTIM AQ is a recombinant follicle-stimulating hormone (FSH) administered via subcutaneous injection for fertility treatment. It is used to stimulate ovarian follicle development in women undergoing assisted reproductive technology (ART) and to treat hypogonadism in men. The drug works by mimicking the body's natural FSH to promote gamete production.
LOE Approaching
Product faces moderate competitive pressure (30/100) with LOE approaching, signaling transition from growth-stage to mature/declining phase requiring defensive commercial strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FOLLISTIM AQ offers stable career exposure in specialty/fertility pharma within a mature product requiring defensive commercial and regulatory expertise. This role emphasizes market access, reimbursement strategy, and preparation for competitive/biosimilar landscape shifts rather than high-growth launch activities.
Brand ManagerMedical Science Liaison
Worked on FOLLISTIM AQ at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.